摘要
目的对比分析补钠治疗与限钠治疗在肝硬化腹水合并低钠血症患者临床治疗中的效果。方法选取本院2010年1月～2012年12月收治的98例肝硬化腹水合并低钠血症患者．随机分成补钠组和限钠组．每组49例。，两组患者均进行2周常规治疗，观察其腹水程度、临床疗效和相关并发症发生率。结果补钠组的腹水程度明显低于限钠组，补钠组的临床疗效明显高于限钠组，差异有统计学意义（P〈O．05）；补钠组的肝性脑病、肝肾综合征、自发性腹膜炎和消化道出血发生率均明显低于限钠组，差异有统计学意义（P〈O．05）。结论肝硬化腹水合并低钠血症患者易发生肝性脑病、肝肾综合征等并发症，其腹水程度往往较高，治疗效果较差，易导致预后不良，补钠治疗较限钠治疗有明显优势，在临床工作中具有重要意义，值得推广应用。
Objective To compare and analyze clinical therapeutic effect of sodium supplement therapy and sodium restriction therapy in the treatment of patient with liver cirrhosis ascites combined with hyponatremia.nethods 98 cases of patients with liver cirrhosis ascites combined with hyponatremia in our hospital from January 2010 to December 2012 were selected and randomly assigned to sodium supplement group and sodimn restriction group,wilh 49 patients in each group.After routine treatment of two weeks,degree of ascites,clinicaI effect,the incidence of related complication in two groups were observed.Results Degree of ascites in sodium supplement group significantly lower than that in sodium restriction group,clinical effect of sodium supplement group significantly higher than that of stadium restriction group,with statistical difference（P〈0.05）.The incidence rate of hepatic encephalopathy,hepatorenal syndrome, spontaneous peritonitis and alimentary tract hemorrhage in sodium supplement group significanlly lower than that in sodium restriction group,with statistical difference （P〈0.05）.Conclusion Patients with liver cirrhosis ascites combined with hyponatremia susceptible to hepatic encephalopathy,hepatorenal syndrome,which is often higher degree,trealment effect is poor, easily lead to poor prognosis.Compared with sodium restriction therapy,sodium supplenlent therapy has obvious advantage and important significance in clinic.It is worthy of popularization and application.
出处
《中国当代医药》
2014年第2期181-182,187,共3页
China Modern Medicine
关键词
肝硬化
腹水
低钠血症
Liver cirrhosis
Ascites
Hyponatremia
